1377323-72-2

Upstream product

• 1377323-80-2 3-[(dimethylamino)methyl]-5-fluorophenol 
• 1377323-74-4 2-cyano-1-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylmethyl)ethyl methanesulfonate 
• 1377323-77-7 4-(4-hydroxypiperidin-1-yl)-3-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile 
• 1377323-76-6 4-(4-oxopiperidin-1-yl)-3-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile 
• 1377323-75-5 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-3-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]butanenitrile 
• 1023290-12-1 3-fluoro-5-hydroxybenzaldehyde 
• 473923-95-4 3-fluoro-5-hydroxy-benzonitrile 
• 177-11-7 4,4-ethylenedioxy-piperidine 

Relevant academic research and scientific papers

JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES

This invention relates to JAK1 selective inhibitors, particularly pyrrolo[2,3-d]pyrimidine and pyrrolo[2,3-b]pyridine derivatives, and their use in treating myelodysplastic syndromes (MDS).

HETEROCYCLIC-SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRIMIDINES AS JAK INHIBITORS

The present invention provides heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines of Formula I: wherein X, Y, Z, L, A, R5, n, m, and r are defined above, as well as their compositions and methods of use, that modulate the activity